Hofseth BioCare ASA: Extraordinary General Meeting completed

Core Insights - Hofseth BioCare ASA (HBC) held an Extraordinary General Meeting on November 20, 2025, where all proposals were approved as per the notice issued on October 30, 2025 [1] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability, optimal utilization of natural resources, and full traceability [1] - The company upcycles byproducts from the salmon industry, converting waste into health-improving ingredients for humans and pets [1] Product Offerings - Key products include ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a whole salmon oil; and CalGo® / NT-II®, a salmon bone powder for bone and joint health [2] - ProGo® enhances iron metabolism, leading to increased energy and vitality, while OmeGo® supports immune health and recovery from viral infections [3] - CalGo® promotes bone and joint health, aiding healthy aging and active lifestyles [3] Scientific and Academic Partnerships - HBC emphasizes scientific evidence, resulting in academic partnerships and the identification of unique health benefits [3] - The company has secured patents for its discoveries and has spun out a biotech-focused entity, HBC Immunology (HBCI), which is developing therapeutics for prostate and ovarian cancer, as well as an oral therapy for asthma [3] Corporate Structure - HBC is headquartered in Ålesund, Norway, with branches in Oslo, London, Zürich, and Palo Alto [4] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [4]